Jazz Pharmaceuticals plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Jazz Pharmaceuticals plc (JAZZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $21.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-24
- Jazz Pharmaceuticals plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $21.70M, a 10750.00% increase from fiscal 2024.
- Jazz Pharmaceuticals plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $200.00K, a 96.83% decline from fiscal 2023.
- Jazz Pharmaceuticals plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $6.30M, a 81.90% decline from fiscal 2022.
- Jazz Pharmaceuticals plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $34.80M, a 32.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $21.70M 10-K · filed 2026-02-24 |
| 2024-12-31 | $200.00K 10-K · filed 2026-02-24 |
| 2023-12-31 | $6.30M 10-K · filed 2026-02-24 |
| 2022-12-31 | $34.80M 10-K · filed 2025-02-26 |
| 2021-12-31 | $51.80M 10-K · filed 2024-02-28 |
| 2020-12-31 | $26.40M 10-K · filed 2023-03-01 |
| 2019-12-31 | $26.20M 10-K · filed 2022-03-01 |
| 2018-12-31 | $43.40M 10-K · filed 2021-02-23 |
| 2017-12-31 | $38.90M 10-K · filed 2020-02-25 |
| 2016-12-31 | $36.10M 10-K · filed 2019-02-26 |
| 2015-12-31 | $93.30M 10-K · filed 2018-02-27 |
| 2014-12-31 | $138.20M 10-K · filed 2017-02-28 |
| 2013-12-31 | $46.00M 10-K · filed 2016-02-23 |
| 2012-12-31 | $106.50M 10-K · filed 2015-02-24 |
| 2011-12-31 | $33.50M 10-K · filed 2014-02-25 |
| 2010-12-31 | $9.70M 10-K · filed 2013-02-26 |
| 2009-12-31 | $18.00K 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |